The 'FOREST' platform, a pioneering RNA library vs. Compound (CPD) library screening technology providing comprehensive RNA-compound binding data of all combinations. Our drug discovery strategy is to find CPDs with high binding affinity and selectivity by leveraging high-resolution, large-scale data and advanced analytics for RNA structure-targeted drug discovery. We utilize NGS-based assays for the precise prediction of binding sites between nucleobases and hit compounds. This approach grants a unique ability to determine the binding strength and selectivity between compounds and RNA, thereby enabling the prediction of potential side effects.